PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Transplantation. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
Transplantation. 1991 September; 52(3): 519–522.
PMCID: PMC2967388
NIHMSID: NIHMS242135

IN VIVO EFFECT OF FK506 ON HUMAN PANCREATIC ISLETS1

Abstract

The purpose of this study was to evaluate the in vivo effect of FK506 on human pancreatic islets. Twenty-five nude mice were made diabetic by one intravenous injection of streptozotocin. Approximately 600 islets were administered in the renal subcapsular space 3–5 days following streptozotocin administration. One week after transplantation, the mice were divided in four groups. In group 1, the animals received 1 injection of 0.5 ml of diluent i.p. daily for one week. In groups 2, 3, and 4 the treatments were daily i.p. injection of 0.3, 1, and 3 mg/kg FK506, respectively. After treatment, the functional integrity of the transplanted human islets was tested by measuring the plasma glucose and human C-peptide response to intraperitoneal glucose injection in groups 1 and 4. IPGTT alone was assessed in groups 2 and 3. The results indicate that i.p. administration of FK506 for one week at a dose 0.3 mg/kg/day did not result in any significant alteration of glucose disappearance and C-peptide response to IPGTT. Higher doses of FK506 produced a significant delay in glucose disappearance in groups 3 and 4, and a significant inhibition of glucose-mediated C-peptide response in group 4.

FK506 has recently joined the growing list of new pharmaceuticals with potent immunosuppressive properties (1). Post-transplant hyperglycemia is a well recognized side effect of most standard immunosuppressive drugs, including prednisone (2) and cyclosporine A (35), which are known to be diabetogenic in men. Similar effects have been ascribed to FK506 in both experimental (6, 7) and clinical studies (8). As clinical experience is successfully extended, there will be new applications for the drug besides whole organ transplantation. FK506 has been recently used as a main immunosuppressive agent in clinical trials of islet transplantation (9). In addition, intervention trials of FK506 in the treatment of new-onset type I diabetes mellitus are planned. The aim of this study was to test the in vivo effect of FK506 on human pancreatic islets.

MATERIALS AND METHODS

Human islet isolation

Human islets were prepared from cadaver donor pancreases obtained from multiorgan donors (10, 11). After in situ perfusion of the abdominal aorta with 1500–2000 ml of University of Wisconsin solution (UW) additional 500–1000 ml of UW was infused directly into the liver via the portal vein. Venous hypertension of the pancreas was avoided by venting the portal and/or splenic vein. The pancreas was immersed in UW and packed in ice until the islet isolation began. The islets were isolated as previously described (9, 12). Briefly, after intraductal injection of 350 ml of Hanks’ solution containing 2 mg/ml collagenase (Boehringer-Mannheim, type P) the pancreas was loaded into a stainless steel digestion chamber and the islets were separated during a continuous digestion process that lasted 40–50 min (12). The islets were purified by centrifugation on Eurocollins-Ficoll gradients (density = 1.108, 1.096, 1.037) using a COBE 2991 cell separator (COBE Laboratories, Lakewood, CO) (9).

Animals

Male BALB/c nude mice (16–20 g body weight) were used an islet recipients. The animals were made diabetic by one intravenous injection of streptozotocin (165 mg/kg).

Human islet transplantation

Only mice with nonfasting plasma glucose >400 mg/dl were used a recipients of human islets. Each animal received an aliquot of approximately 600 human islets of 150-μ diameter (13) 3–5 days after streptozotocin administration. The islets were transplanted beneath the left renal capsule as previously described (14).

Treatment

FK506 (10 mg) was dissolved in a mixture of cremaphor (625 mg) and ethanol (328 mg). This solution was diluted with normal saline to give a concentration of 100 mg/ml. The saline solution of FK506 was prepared fresh daily for injection.

One week after human islet transplantation the animals were divided in four groups. In group 1 (n=10), the animals received one injection of 0.5 ml of cremaphor-ethanol-saline (without FK506) i.p. daily for one week. In group 2 (n=5) the animals were treated by daily i.p. injection of 0.3 mg/kg FK506, while in groups 3 (n=5) and 4 (n=5) the daily injections were 1 and 3 mg/kg FK506, respectively.

Intraperitoneal glucose tolerance test

At 15 days after islet transplantation, the animals underwent IPGTT (15). The animals were fasted overnight (18 hr) and then injected intraperitoneally with 25% glucose and 0.9% sodium chloride solution (2 g glucose/kg body weight). Blood samples were obtained before (0 min) and 15, 30, and 60 min after glucose injection and analyzed for plasma glucose and human C-peptide levels.

Plasma glucose and human C-peptide determination

Whole-blood (100 μl) was collected into microhematocrit capillary tubes and placed on ice. Plasma was prepared by centrifugation at 10,000 ×g for 3 min in a microcentrifuge, and plasma glucose was measured with Beckman Glucose Analyzer II (Fullerton, CA). Blood samples for human C-peptide determination were collected as previously described for serum insulin (16). C-peptide was analyzed only in groups 1 and 4. A 20-μl sample of blood was diluted in 200 μl of saline, and the serum separated and stored at −20°C until radioimmunoassay. Human C-peptide was assayed by a double-antibody 126I radioimmunoassay (17). The human C-peptide standard solutions and the rabbit antihuman C-peptide (serum K6) were obtained from NOVO Biolabs (Danbury, CT). The human mono 126I Tyr-C-peptide was a gift from Eli Lilly and Company, Indianapolis, IN.

Determination of FK506 blood levels

Immediately after IPGTT the animals of group 2. 3, and 4 were sacrificed and the blood collected for determination of FK506 levels. The FK506 assay was performed by the modified enzyme immunoassay (18) using a mouse monoclonal anti-FK506 antibody (Fujisawa Pharmaceuticals Co. Ltd, Osaka, Japan).

Histologic studies

The kidneys bearing the human islet transplants were excised for determination of morphologic integrity of the human islets grafts. In group 1 (control) a nephrectomy of the kidney bearing the graft was performed to demonstrate that the human islet transplants were responsible for the maintenance of normoglycemia. Histologic integrity of the renal subcapsular graft was determined by hematoxylin and cosin stain and by immunoperoxidase (insulin) stain.

Statistical analysis

All results are expressed as means ± SD. ANOVA was used to compare differences between groups, and P values are given as measures of statistical significance.

RESULTS

The results are summarized in Tables 1 and and22 and in Figures 1 and and2.2. Intraperitoneal administration of FK506 for one week at a dose of 0.3 mg/kg/day did not produce any significant alteration of glucose disappearance after intraperitoneal administration of glucose. Higher doses of FK506 produced a significant delay in plasma glucose disappearance. In group 3 and 4, 2 of 10 animals demonstrated hyperglycemia before IPGTT (fasting plasma glucose >200 mg/dl). In these animals, the presence of fasting hyperglycemia despite normal levels of human C-peptide indicated that peripheral insulin resistance could be responsible for the hyperglycemic effect of FK506. Nevertheless, with high-dose treatment insulin secretion appears to be impaired as well. Furthermore, 5 of 10 animals remained hyperglycemic 1 hour after intraperitoneal glucose injection. Human C-peptide levels following IPGTT indicated that abnormal glucose disappearance in group 4 was associated with an initial impairment of insulin secretion from the engrafted islets. In fact, 15 min after glucose injection a decrease in human C-peptide levels was observed in group 4, in contrast to the control groups, in which a two fold increase in C-peptide was observed. The difference in C-peptide levels between the two groups was statistically significant only at the 15-min level (P<0.028).

Figure 1
Plasma glucose levels during intraperitoneal glucose tolerance test 15 days after human islet transplantation in the renal subcapsular space of diabetic nude mice.
Figure 2
Human C-peptide levels during an intraperitoneal glucose tolerance test 15 days after human islet transplantation in the renal subcapsular space of diabetic nude mice.
Table 1
Intraperitoneal glucose tolerance test—plasma glucose (mg/dl)a
Table 2
Intraperitoneal glucose tolerance test—human C-peptide (pmol/ml)a

The determination of plasma FK levels after IPGTT resulted in an average of 3.8±2.8 ng/ml (group 2), 106.6±6.3 ng/ml (group 3), and 303.5±173.7 ng/ml (group 4).

Histologic studies of the renal subcapsular islets indicated that human islets were present in the renal subcapsular space of all transplanted animals. Nevertheless, in the 2 animals (1 in group 3 and 1 in group 4) who were hyperglycemic, the beta cells appeared degranulated. In the remaining animals the human islets appeared well-preserved, with no significant difference between FK506 treated and control animals. In group 1 (control) a nephrectomy of the kidneys bearing the grafts produced a rapid return to the diabetic state, indicating that the human islets transplanted were responsible for the maintenance of normoglycemia.

DISCUSSION

This study indicates that FK506 did not produce significant alteration of glucose homeostasis in animals treated with a dose of 0.3 mg/kg/day for 7 days. Nevertheless, the effects of the drug on insulin secretion and glucose disappearance after intraperitoneal glucose have been observed at higher doses. These effects appear to be dose-dependent and are observed with serum FK506 levels that are significantly higher than therapeutic levels achieved in man. Although these levels are significantly higher than the therapeutic levels in current use in patients, the potential accumulation during chronic treatment with the agent in the pancreas, like cyclosporine, may induce islet secretory defects even at therapeutic levels. In addition, the pharmacodynamics of FK506 may differ between the two species.

These findings confirm the results of previous reports on the effect FK506 on rat and human islets in vitro (19). Further studies are needed to determine whether the toxic effect of FK506 observed at higher doses is reversible upon discontinuation of treatment.

Footnotes

1This work was supported by Research Grants from the Veterans Administration and by Project Grant 29961 from the National Institutes of Health, Bethesda, MD.

References

1. Starzl TE, Todo S, Fung JJ, Groth C, editors. Transplant Proc. Vol. 22. 1990. FK506, a potential breakthrough in immunosuppression—clinical implications; p. 5. [PubMed]
2. David DS, Cheigh JS, Braun DW, Fontino M, Stenzel KH, Rubin AL. HLA-A28 and steroid induced diabetes in renal tranaplant patients. JAMA. 1980;243:532. [PubMed]
3. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allografts recipients. Transplantation. 1987;44:376. [PubMed]
4. Ost L, Tyden T, Fehrman I. Impaired glucose tolerance in cyclosporine-prednisolone–treated renal graft recipients. Transplantation. 1988;46:370. [PubMed]
5. Roth D, Milgram M, Esquenzal V, Laphalle F, Burke G, Miller J. Posttransplant hyperglycemia. Transplantation. 1989;47:278. [PubMed]
6. Nalesnik MA, Todo S, Murase N, et al. Toxicology of FK506 in the Lewis rat. Transplant Proc. 1987;19:79. [PMC free article] [PubMed]
7. Collier DSJ, Calne R, Thiru S, et al. FK506 in experimental renal allografts. Transplant Proc. 1987;19:3975. [PubMed]
8. Mieles L, Todo S, Fung JJ, et al. Oral glucose tolerance test in liver recipients treated with FK506. Transplant Proc. 1990;22:41. [PMC free article] [PubMed]
9. Tzakis A, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336:402. [PMC free article] [PubMed]
10. Starzl TE, Miller C, Broznick B, Makowka L. An improved technique for multiple organ harvesting. Surg Gynecol Obstet. 1987;165:343. [PMC free article] [PubMed]
11. Starzl TE, Todo S, Tzakis A, et al. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg. 1989;210:374. [PubMed]
12. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37:413. [PubMed]
13. Ricordi C, Gray DWR, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Latina. 1990;27:185. [PubMed]
14. Ricordi C, Lacy PE, Stezbent K, Davie JM. Low temperature culture of human islets or in-vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival. Proc Natl Acad Sci USA. 1988;84:234. [PubMed]
15. Kaku K, Fiedorek FT, Province M, Permutt MA. Genetic analysis of glucose tolerance in inbred mouse strains. Diabetes. 1988;37:707. [PubMed]